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An intra-bacterial activity for a 
T3SS effector
Samir el Qaidi1, nichollas e. Scott2, Michael p. Hays1, Brian V. Geisbrecht3, Shelby Watkins1 & 
philip R. Hardwidge1*
Many Gram-negative bacterial pathogens interact with mammalian cells by using type iii secretion 
systems (T3SS) to inject virulence proteins into host cells. A subset of these injected protein ‘effectors’ 
are enzymes that inhibit the function of host proteins by catalyzing the addition of unusual post-
translational modifications. The E. coli and Citrobacter rodentium NleB effectors, as well as the 
Salmonella enterica SseK effectors are glycosyltransferases that modify host protein substrates with 
N-acetyl glucosamine (GlcNAc) on arginine residues. This post-translational modification disrupts the 
normal functioning of host immune response proteins. T3SS effectors are thought to be inactive within 
the bacterium and fold into their active conformations after they are injected, due to the activity of 
chaperones that keep the effectors in a structural state permissive for secretion. While performing mass 
spectrometry experiments to identify glycosylation substrates of nleB orthologs, we unexpectedly 
observed that the bacterial glutathione synthetase (GshB) is glycosylated by NleB on arginine residue 
R256. NleB-mediated glycosylation of GshB resulted in enhanced GshB activity, leading to an increase 
in glutathione production, and promoted C. rodentium survival in oxidative stress conditions. these 
data represent, to our knowledge, the first intra-bacterial activity for a T3SS effector and show that 
arginine-GlcnAcylation, once thought to be restricted to host cell compartments, also plays an 
important role in regulating bacterial physiology.
The NleB (Escherichia coli and Citrobacter rodentium) and SseK (Salmonella enterica) enzymes are type three 
secretion system (T3SS) effector proteins that glycosylate host proteins with N-acetyl glucosamine (GlcNAc) on 
arginine residues to subvert their function in the innate immune system1–3. Arginine glycosylation is unusual 
because it occurs on the guanidinium groups of arginines, which are poor nucleophiles. The NleB/SseK orthologs 
share high degrees of structural similarity and consist of a catalytic domain including essential DXD and HEN 
motifs, a helix-loop-helix (HLH) domain, and a C-terminal lid domain4–6. Several ‘death domain’-containing 
proteins such as the Fas-Associated protein with Death Domain (FADD), tumor necrosis factor receptor type 
1-associated death domain protein (TRADD), and the receptor interaction serine/threonine-protein kinase 1 
(RIPK1) are NleB/SseK substrates2. These effectors disrupt tumor necrosis factor receptor (TNFR)-associated 
factor (TRAF) signaling, leading to inhibition of the pro-inflammatory NF-κB pathway1–3.
T3SS effectors are chaperoned in the bacterium after their synthesis to keep them partially unfolded and 
competent for secretion, as well as for targeting the effectors to the T3SS sorting platform7. The chaperones are 
then stripped from their effector substrates at the sorting platform and the effectors are secreted in an unfolded 
conformation8. T3SS effectors are generally believed to be inactive until they are injected into host cells, where 
they then fold into their active conformations9.
Some precedent for type IV secretion system (T4SS) effector activity in both the bacterium and the host may 
exist in plant pathogens. Agrobacterium tumefaciens transfers a nucleoprotein complex into plant cells. The VirD2 
protein is associated with the transferred DNA (T-DNA). VirD2 has endonuclease activity within the bacterium 
to initiate T-DNA transfer10. VirD2 also targets the nucleoprotein complex in the plant cell nucleus, where it 
assists in integrating T-DNA into plant chromosomes11. Therefore, VirD2 may have enzymatic functions both 
within the bacterium and in the host plant cell. A recent study also indicated that Yersinia pseudotuberculosis uses 
the secreted T3SS translocator YopD to control RNA regulators and increase the abundance of LcrF, a common 
transcriptional activator of other T3SS effector genes12.
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N-linked protein glycosylation on arginine has also been reported for the EarP glycosyltransferase from E. coli 
and Pseudomonas aeruginosa13. In this case, a single arginine rhamnosylation event activates the function of the 
polyproline-specific bacterial translation elongation factor EF-P13. Although the relatively inert guanidine group 
of arginine was previously thought to impede nucleophilic attack onto donor substrates, it is now clear that many 
bacterial enzymes have overcome this barrier. The enzymology and functional roles of arginine glycosylation, 
methylation, phosphorylation, and ADP-ribosylation were recently reviewed14.
While characterizing additional NleB glycosylation substrates, we made the unexpected observation that the 
bacterial glutathione synthetase (GshB) is glycosylated by NleB on an arginine residue. This glycosylation con-
tributes to bacterial survival in hydrogen peroxide stress conditions by enhancing GshB activity and increasing 
intracellular levels of glutathione (GSH). Thus, NleB is active and performs important biological functions within 
the bacterium, prior to its secretion.
Results
nleB glycosylates GshB. We performed mass spectrometry experiments to identify new glycosylation 
substrates of NleB orthologs from EHEC strains associated with human disease outbreaks. These experiments 
were conducted by infecting HEK293T cells with EHEC strains that express NleB1. We then used an anti-Arg-
R-GlcNAc monoclonal antibody15 for the antibody-based capture of arginine-GlcNAcylated peptides to perform 
proteome-wide assessment of Arg-GlcNAcylation mediated by NleB1, as described previously16. We unexpect-
edly observed glycosylation of E. coli glutathione synthetase (GshB) on arginine residue R256 as the most abun-
dant Arg-GlcNAcylated peptide enriched from samples, followed by the known human NleB1 target FADD16 
(Supp. Table 1).
Because C. rodentium encodes only one copy of NleB, while most EHEC strains encode two copies (NleB1 and 
NleB2), we subsequently attempted to reproduce our initial findings using C. rodentium NleB and GshB using 
in vivo4 or in vitro17 studies to investigate glycosylation within this protein. Using these assays, we observed that 
GshB is exclusively modified on R256, with this glycosylation event absent in GshB(256 A) expressing strains 
[Fig. 1A; -log10(p-value) of 1.77 and 2.78 from in vivo and in vitro assays respectively, Supp. Table 2]. To fur-
ther test the localization of the glycosylation, in vivo glycosylated GshB was subjected to Electron-Transfer/
Higher-Energy Collision Dissociation (EThcD) fragmentation, confirming the attachment of the GlcNAc residue 
to R256 (Fig. 1B). These data support the notion that the glutathione synthetase GshB from the attaching/effacing 
pathogens EHEC and C. rodentium is glycosylated at R256 under in vivo conditions.
To corroborate our mass spectrometry data, we conducted in vitro glycosylation assays17 with the 
Anti-R-GlcNAc monoclonal antibody15 by expressing recombinant forms of wild-type (WT) GshB or 
GshB(256 A). NleB glycosylated the WT, but not the R256A GshB mutant (Fig. 1C), consistent with our in vivo 
and in vitro MS assays. Within these assays, FADD was used as a positive control as a known NleB substrate16. The 
NleB(AAA) mutant, which lacks glycosylation activity1, was used as a negative control.
We then generated a gshB deletion in C. rodentium and complemented this mutant with FLAG-tagged ver-
sions of either WT or GshB(R256A). Both FLAG-tagged forms of GshB were isolated from C. rodentium; only 
WT GshB was glycosylated by the endogenous levels of NleB (Fig. 1D). Neither secretion of GshB nor its gly-
cosylation in the culture medium by NleB was observed, suggesting that NleB glycosylation of GshB occurred 
within the bacterium.
nleB promotes oxidative stress resistance. Glutathione (GSH) is generated in Gram-negative bacteria 
in a two-step process by γ-glutamylcysteine synthetase (gshA) and glutathione synthetase (gshB). GshA uses 
glutamate and cysteine as substrates to catalyze the formation of γ-L-glutamylcysteine. GshB catalyzes GSH pro-
duction by ligating glycine and γ-L-glutamylcysteine18. Salmonella lacking either enzyme do not produce GSH 
and exhibit increased susceptibility to oxidative stress19. A Salmonella gshA deletion is hypersensitive to H2O2, 
and gshA and gshB deletions are hypersensitive to both nitric oxide (NO) and S-nitrosoglutathione (GSNO)19. 
Similarly, in Pseudomonas aeruginosa, gshA and/or gshB deletions are more sensitive to environmental stress and 
attenuated for virulence20. In Streptococcus pneumoniae, mutating gshT, an ABC transporter required for GSH 
import, increased S. pneumoniae sensitivity to superoxide, and was attenuated in a mouse model of infection21. 
Deleting gshA and gshB from P. aeruginosa attenuates several virulence-associated phenotypes including motility 
and biofilm formation. GSH was also shown to activate both the P. aeruginosa T3SS and a subset of T6SS genes22. 
Glutathione binding to the Listeria monocytogenes master regulator PrfA is also critical to the virulence of this 
intracellular pathogen23.
To determine whether GshB glycosylation by NleB has functional significance in promoting resistance to 
oxidative stress, we compared the growth rates of bacterial strains in the presence or absence of H2O2. Both the 
nleB and gshB mutants had a significant growth defect in the presence of H2O2 (Fig. 2A), despite having similar 
growth rates in the absence of H2O2 (Fig. 2B). The nleB mutant phenotype was complemented by expressing WT 
nleB on a plasmid, but not by expressing the inactive nleB(AAA) mutant. Mutating the GshB R256 residue to 
alanine (R256A) had no impact on bacterial growth rates. These data highlight a new role for NleB, namely its 
requirement for C. rodentium survival in peroxide stress conditions.
Arg-glycosylation enhances GshB activity. We then tested the hypothesis that GshB glycosylation 
enhances GshB-mediated production of glutathione (GSH), consistent with the bacterial growth phenotypes 
in the presence of H2O2. We incubated C. rodentium lysates prepared from cultures grown in the presence or 
absence of 2.4 mM H2O2 with glutathione S-transferase (GST) and 1-chloro-2,4-dinitrobenzene (CDNB) to 
quantify GSH concentrations in bacterial lysates24. The WT strain produced significantly more GSH (3.4 + 0.9 
pmoles/s) than did the nleB mutant (2.3 + 0.6 pmoles/s), irrespective of the presence of H2O2 (Fig. 3A,B). To 
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verify that the growth defect of the nleB-deleted strain in H2O2 was due to insufficient GSH, we supplemented 
bacterial cultures with 5.0 mM GSH and observed partial restoration of the growth of the nleB mutant in the 
presence of H2O2 (Fig. 3C).
Figure 1. NleB glycosylates GshB R256. (A) Heatmap of Z-scored ion intensities of GshB peptides 
demonstrates that glycosylated R256 is observed only within WT GshB samples in both in vivo and in 
vitro glycosylation assays. The abundance of non-glycosylated peptides 109GTLIVNKPQSLRDCNEK125, 
88DPPFDTEFIYATYILERAEEK108 and 145AQLKAFWEK153 are unaltered across assays (B) EThcD spectra of the 
in vivo glycosylated GshB peptide 254IARQIGPTLK263 confirms glycosylation is localized to R256. (C) Western 
blot analysis of in vitro GshB glycosylation assays. (D) Western blot analysis of in vivo GshB glycosylation assays; 
Sup, culture supernatant; Pel, bacterial lysate.
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We then reconstituted an in vitro GSH production assay using purified, recombinant GshA, GST, as well as 
GshB that was purified from E. coli BL21(DE3), following its co-expression with either NleB or NleB(AAA) 
(Fig. 4A). Thus, we aimed to generate either glycosylated GshB (when co-expressed with WT NleB) or unglyco-
sylated GshB [when mutated to R256A and/or when WT GshB was co-expressed with NleB(AAA)] to directly 
characterize the impact of GshB glycosylation on GshB activity. Glycosylation of GshB on R256 in this assay was 
confirmed using western blotting, showing that NleB was active when expressed in E. coli BL21(DE3) (Fig. 4B). 
The GshB enzyme purified from the WT NleB co-expression strain was significantly more active than the GshB 
enzyme purified from the NleB(AAA) co-expression strain (1.5 + 0.1 vs. 1.0. + 0.1 pmoles/s) (Fig. 4C). NleB had 
no impact on GSH production catalyzed by GshB(R256A). We obtained similar data when GshB was first purified 
from E. coli and then subsequently glycosylated by NleB in vitro (Fig. S1).
We also considered whether Salmonella might glycosylate GshB in vivo. We did not observe such glycosylation 
under conditions performed similarly to those using C. rodentium (Fig. S2A). However, Salmonella is significantly 
more resistant to H2O2 than is C. rodentium, due to the presence of redundant catalases and alkyl hydroperoxide 
reductases25–27. Consistent with this, we failed to observe a growth phenotype when we subjected WT Salmonella 
and all possible combinations of sseK1/K2/K3 mutants to 12.0 mM H2O2, a concentration 5-times greater than 
that used for C. rodentium experiments (Fig. S2B). These data suggest that the SseK enzymes are not significantly 
involved in H2O2 resistance by Salmonella.
However, we further considered the possibility that some degree of GshB glycosylation might be observed in 
vitro using purified recombinant proteins. We especially considered this because of previous findings demonstrat-
ing that NleB/SseK substrate specificity may be more broad in vitro as compared to in vivo assays, particularly 
when the enzyme is present at supraphysiological concentration16. We incubated GshB with all known NleB/
SseK orthologs from EHEC, EPEC, C. rodentium, and Salmonella and observed that EHEC NleB1, EPEC NleB1, 
and Salmonella SseK1 all glycosylated GshB, whereas NleB2, SseK2, and SseK3 did not (Fig. S2C). Whether GshB 
glycosylation by EHEC and/or EPEC NleB1 may affect oxidative stress resistance in these attaching/effacing 
pathogens awaits further experimentation.
Although no chaperone for NleB has been identified, we also considered whether the presence of CesT, a 
multi-cargo chaperone that interacts with at least 9 other effectors28, might affect NleB activity. We especially 
considered this possibility because effector-binding and secretion activities are separable for CesT29. However, 
we did not observe any impact on NleB activity in a C. rodentium cesT mutant (Fig. S2A), nor did we observe 
an interaction between NleB and CesT, as assessed using affinity chromatography (data not shown). Thus, NleB 
activity appears to be independent of CesT.
Discussion
NleB is an arginine glycosyltransferase that modifies several host proteins, leading to inactivation of the host 
pro-inflammatory response mediated by NF-κB4,6. Here we discovered that NleB also plays a significant role in 
bacterial survival in oxidative stress conditions by glycosylating GshB to enhance GSH production. In this case, 
rather than inactivating the NleB substrates, as is seen with the mammalian targets, Arg-GlcNAcylation signif-
icantly activates the bacterial GshB enzyme. It remains to be determined why GshB glycosylation enhances its 
enzyme activity. The glycosylated R256 is distant from the active site (Fig. S2B), as inferred from the E. coli GshB 
structure [PDB 1GSA;30]. Possible mechanisms could include changes in GshB oligomerization state, a conforma-
tional change of the GshB active site, or enhanced affinity for/localization with GshA.
Figure 2. C. rodentium growth assays. (A) Quantification of C. rodentium growth (OD600) as a function of time 
(min) in the presence of 2.4 mM H2O2. (B) C. rodentium growth in the absence of H2O2.
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GshB is an abundant cytoplasmic protein31. In our assays, we observed a 50–100% increase in GshB activity 
(Figs. 3–4), despite only a relatively low degree of overall GshB Arg-GlcNAcylation (occupancy of ~5%, Supp. 
Table 1). It is therefore possible that Arg-GlcNAcylation may increase GshB activity by as much as 10-fold. Formal 
testing of this hypothesis awaits the complete separation of glycosylated from unglycosylated forms of GshB.
NleB/SseK activities in the host cell have been characterized for their inhibition of proteins involved in the 
innate immune response1–4,6. Previous work with Ear-P showed that Arg-rhamnosylation activates EF-P in the 
bacterial cytosol13, to avoid ribosome stalling during the synthesis of poly-proline regions32. It is now clear from 
our work that Arg-GlcNAcylation also provides an important activating function, namely the NleB-mediated 
activation of GshB through R256 glycosylation. The abundance and functional significance of cytoplasmic bacte-
rial glycoproteins may be a fruitful area for future studies.
Regardless of the specific activating mechanism, these data represent, to our knowledge, the first example of a 
T3SS effector functioning within both the bacterium and within the host cell. It is possible that other C. rodentium 
proteins are glycosylated by NleB to provide the organism a means by which to integrate T3SS activation and 
effector synthesis with bacterial physiological processes such as transcriptional regulation, flagellar biosynthe-
sis, and quorum sensing. It is also possible that other T3SS effectors are substrates of NleB, and that other T3SS 
effectors with enzymatic activities are active within the bacterium, a concept similar to the role of metaeffectors 
playing important regulatory roles in Legionella pneumophila biology33. The extent to which other effectors with 
enzymatic activities may be active within the bacterium may emerge as a new area of investigation.
Figure 3. GSH production from bacterial lysates. (A) Bacterial lysates derived from C. rodentium strains grown 
in the absence of H2O2 were incubated with 1 mM CDNB and 1 µM GST. Absorbance was recorded at 340 nm 
every 20 seconds for 10 minutes and OD340 data were converted into GSH concentrations using a GST standard 
curve. (B) GSH production from C. rodentium strains grown in the presence of H2O2. (C) Complementation of 
C. rodentium nleB growth in 2.4 mM H2O2 in the presence or absence of 5.0 mM GSH.
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Materials and Methods
Strains and molecular cloning. The plasmids and strains used in this study are listed in Table 1. WT nleB 
(C. rodentium) and its derivative DAD221–223/AAA were cloned into pET42a. FADD was cloned into pET15a. WT 
gshB and its derivative gshB R256A, as well as gshA, were cloned in pET28a using ABC cloning34. The C. roden-
tium gshB deletion was generated using lambda red recombination35.
Figure 4. In vitro GSH assays. (A) Coomassie blue staining of purified proteins used in GSH assays. (B) 
Western blot analysis of the GshB glycosylation state from GSH assays. (C) GSH production as a function of 
time from reactions containing either WT or GshB(256A) purified after their co-expression with either WT or 
NleB(AAA).
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Protein purification. Proteins were expressed from E. coli BL21 (DE3) and induced with 0.5 mM IPTG 
when cultures reached an OD600 of 0.4. Cells were grown for an additional 4 h at 37 °C and then harvested using 
centrifugation. Cell pellets were resuspended in 1/40th culture volume of 50 mM NaH2PO4 pH 8.0 supplemented 
with 0.5 mg/ml lysozyme and protease inhibitor cocktails (Thermo Scientific). Bacterial suspensions were incu-
bated on ice for 30 min with occasional shaking, at which time an equal volume 50 mM NaH2PO4 pH 8.0, 2 M 
NaCl, 8 mM imidazole, 20% glycerol, 2% Triton X-100 was added for additional incubation on ice for 30 min. Cell 
lysates were sonicated, centrifuged, and combined with 2 ml Ni-NTA slurry (Qiagen) for 1 h at 4 °C with gentle 
rotation. The mixture was loaded on a Poly-Prep Chromatography Column (Bio-Rad) and washed in 50 mM 
Plasmid Source
FLAG-NleB (C. rodentium) 1
FLAG-NleB (C. rodentium) (DAD221–223/AAA) 1
GST-NleB (C. rodentium) 17
GST-NleB (C. rodentium) (DAD221–223/AAA) 17
GST-NleB1 (EHEC) 17
GST-NleB1 (EPEC) 17
GST-NleB2 17
GST-SseK1 (S. enterica) 17
GST-SseK2 (S. enterica) 17
GST-SseK3 (S. enterica) 17
His-FADD 17
His-GshA This study
His-GshB This study
His-GshB(R256A) This study
FLAG-His-GshB This study
FLAG-His-GshB(R256A) This study
His-CesT This study
His-GST Novagen
Strain Source
C. rodentium DBS100 44
C. rodentium DBS100 ΔnleB 1
C. rodentium DBS100 ΔnleB/pFLAG-CTC-nleB 1
C. rodentium DBS100 ΔnleB/pFLAG-CTC-nleB 
DAD221–223/AAA
1
C. rodentium DBS100 ΔcesT 45
C. rodentium ΔgshB This study
C. rodentium ΔgshB/pFLAG-CTC gshB This study
C. rodentium ΔgshB/pFLAG-CTC gshB(R256A) This study
S. enterica 46
S. enterica ΔsseK1 46
S. enterica ΔsseK2 46
S. enterica ΔsseK3 46
S. enterica ΔsseK1ΔsseK2 46
S. enterica ΔsseK1ΔsseK3 46
S. enterica ΔsseK2ΔsseK3 46
S. enterica ΔsseK1ΔsseK2ΔsseK3 46
E. coli BL21(DE3) x pET28a-gshA This study
E. coli BL21(DE3) x pET28a-gshB This study
E. coli BL21(DE3) x pET28a-gshB(R256A) This study
E. coli BL21(DE3) x pET42a-nleB This study
E. coli BL21(DE3) x pET42a-nleB DAD221-223/AAA This study
E. coli BL21(DE3) x pET42a-nleB1 (EHEC) 17
E. coli BL21(DE3) x pET42a-nleB1 (EPEC) 17
E. coli BL21(DE3) x pET42a-nleB2 17
E. coli BL21(DE3) x pET42a-sseK1 17
E. coli BL21(DE3) x pET42a-sseK2 17
E. coli BL21(DE3) x pET42a-sseK3 17
E. coli O111:NM R82F2 36
Table 1. Plasmids and strains used in this study.
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NaH2PO4 pH 8.0, 600 mM NaCl, 60 mM imidazole, 10% glycerol). Proteins were eluted in 50 mM NaH2PO4 pH 
8.0, 600 mM NaCl, 250 mM imidazole, 10% glycerol and then dialyzed into the same buffer lacking imidazole17.
enrichment of arginine-glycosylated peptides from cell lysates. HEK293T cells were grown in 
DMEM to 80% confluency and then infected with EHEC O111:NM R82F236 at a multiplicity of infection of 1.0 
for 16 h. Infected cells were washed three times in ice-cold PBS and lysed by scraping with ice-cold guanidinium 
chloride lysis buffer (6 M GdmCl, 100 mM Tris pH 8.5, 10 mM TCEP, 40 mM 2-Chloroacetamide) on a bed of ice. 
Lysates were collected and boiled at 95 °C for 10 minutes with shaking at 2,000 rpm to shear DNA and inactivate 
protease activity. Lysates were then cooled for 10 minutes on ice and then boiled again at 95 °C for 10 minutes 
with shaking at 2,000 rpm. Protein samples (2 mg) were acetone precipitated and dried protein pellets were resus-
pended in 6 M urea, 2 M thiourea, 40 mM NH4HCO3 and reduced/alkylated prior to digestion with Lys-C (1/200 
w/w) and then with trypsin (1/50 w/w) overnight as previously described37. Digested samples were acidified to 
a final concentration of 0.5% formic acid and desalted with 50 mg tC18 SEP-PAK (Waters Corporation). tC18 
SEP-PAKs were conditioned with buffer B (80% ACN, 0.1% formic acid), washed with 10 volumes of Buffer A* 
(0.1% TFA, 2% ACN), sample loaded, column washed with 10 volumes of Buffer A* and bound peptides eluted 
with buffer B then dried.
Arg-GlcNAc peptide affinity purification was performed as previously described16. Protein A/G plus Agarose 
beads (Santa Cruz, Santa Cruz CA) were washed with immunoprecipitation buffer (IAP, 10 mM Na2HPO4, 50 mm 
NaCl, 50 mM MOPS, pH 7.2) and rotated overnight with 10 μg of anti-Arg-GlcNAc antibody (ab195033, Abcam) 
at 4 °C. Coupled anti-Arg-GlcNAc beads were then washed with 100 mM sodium borate (pH 9) to remove 
non-bound proteins and cross-linked for 30 minutes of rotation using 20 mM dimethyl pimelimidate in 100 mM 
HEPES, pH 8.0. Cross-linking was quenched by washing beads three times with 200 mM ethanolamine, pH 8.0 
and then rotating the beads in an additional 1 ml of 200 mM ethanolamine, pH 8.0 for 2 hours at 4 °C. Purified 
peptides were resuspended in 1 ml IAP buffer and peptide lysates were then added to the prepared cross-linked 
anti-Arg-GlcNAc antibody beads and rotated for 3 hours at 4 °C. Antibody beads were centrifuged at 3,000 g for 
2 minutes at 4 °C and the unbound peptide lysates collected. Antibody beads were then washed with ice-cold IAP 
buffer and Arg-GlcNAc peptides eluted using two rounds of acid elution. For each elution round, 100 μl of 0.2% 
TFA was added and antibody beads allowed to stand at room temperature with gentle shaking every minute for 
10 minutes. Peptide supernatants were collected and desalted using C18 stage tips38 before being dried down and 
stored until LC-MS analysis.
SP3 on-bead Lys-C digestion of purified GshB. Purified tagged GshB was cleaned up using SP3 based 
purification according to previous protocols39. Samples were first denatured and reduced using 1% SDS, 10 mM 
DTT, 100 mM HEPES by boiling at 95 °C, 1,000 rpm for 10 minutes. Samples were then cooled and alkylated with 
40 mM 2-chloroacetamide (CAA) for 1 hour at RT in the dark. The alkylation reactions were then quenched with 
40 mM DTT for 10 minutes and then samples precipitated on to SeraMag Speed Beads (GE Healthcare, USA) 
with ethanol (final concentration 50% v/v). Samples were shaken for 10 minutes to allow complete precipitation 
onto beads and then washed three times with 80% ethanol. The beads were resuspended in 100 mM ammo-
nium bicarbonate containing 1 μg lys-C 1/50 (w/w) and digested overnight at 37 °C. Samples were centrifuged at 
14,000 g for 5 minutes to pellet the beads and the supernatant collected and desalted using C18 stage tips before 
being dried for LC-MS analysis.
Identification of arginine-glycosylated affinity enriched peptides and his-tagged proteins using 
reversed phase LC-MS. Purified peptides were resuspended in Buffer A* and separated using a two-column 
chromatography setup composed of a PepMap100 C18 20 mm × 75 μm trap and a PepMap C18 500 mm × 75 μm 
analytical column (Thermo Fisher Scientific)16. Samples were concentrated onto the trap column at 5 μl/min 
for 5 minutes and infused into either an Orbitrap Fusion Lumos Tribrid Mass Spectrometer (Thermo Fisher 
Scientific) for the analysis of enriched Arg-GlcNAc peptides and PRM analysis of Arg-GlcNAcylated GshB or an 
Orbitrap Elite (Thermo Fisher Scientific) for the comparison of Arg-GlcNAcylation levels within purified GshB. 
Gradients (120 minutes) were run by altering the buffer composition from 1% buffer B to 28% B over 90 minutes, 
then from 28% B to 40% B over 10 minutes, then from 40% B to 100% B over 2 minutes, the composition was held 
at 100% B for 3 minutes, and then dropped to 3% B over 5 minutes and held at 3% B for another 10 minutes for 
enriched Arg-GlcNAc modified peptides and comparison of Arg-GlcNAcylation levels within purified GshB. For 
120-minute gradients, the Lumos and Elite Mass Spectrometers were operated in a data-dependent mode auto-
matically switching between the acquisition of a single Orbitrap MS scan HCD or CID fragmentation. For parallel 
reaction monitoring (PRM) experiments, the known Lys-C Arg-modified peptide of GshB (IARQIGPTLKEK) 
was monitored using EThcD fragmentation targeting the predicted m/z for the +2 (m/z 650.2835) and +3 charge 
(m/z 488.9248) states over a 95 minute gradient, altering the buffer composition from 1% buffer B to 28% B over 
60 minutes, then from 28% B to 40% B over 10 minutes, then from 40% B to 100% B over 2 minutes, held at 100% 
B for 3 minutes, and then dropped to 3% B over 5 minutes and held at 3% B for another 15 minutes.
Mass spectrometry data analysis. Identification of Arg-glycosylated peptides was accomplished using 
MaxQuant (v1.5.3.30)40. Searches were performed against E. coli O127:H6 strain E2348/69 (Uniprot proteome id 
UP000008205- E. coli O127:H6 strain E2348/69/EPEC, downloaded 28-07-2014, 4,595 entries) or C. rodentium 
ICC168 (Uniprot proteome id UP000001889- C. rodentium strain ICC168 downloaded 12/12/2016) proteomes 
depending on the samples, with carbamidomethylation of cysteine set as a fixed modification. Searches were 
performed with Trypsin or Lys-C cleavage specificity depending on the experiment. Two miscleavage events 
were allowed, as well as the variable modifications of oxidation of methionine, N-Acetylhexosamine addi-
tion to arginine (Arg-GlcNAc) and acetylation of protein N-termini. Precursor mass tolerance was set to 20 
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parts-per-million (ppm) for the first search and 10 ppm for the main search, with a maximum false discovery 
rate (FDR) of 1.0% set for protein and peptide identifications. The Match Between Runs option was enabled with 
a precursor match window set to 2 minutes and an alignment window of 10 minutes. For label-free quantitation, 
the MaxLFQ option within Maxquant41 was enabled, in addition to the re-quantification module. Peptide outputs 
were processed using the Perseus (v1.4.0.6)42 analysis environment to remove reverse matches and common 
protein contaminants with missing values imputed and the peptide intensities z-scored. MS/MS annotations 
were undertaken using the Interactive Peptide Spectral Annotator43. Mass spectrometry proteomics data were 
deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier 
PXD015752.
Glycosylation assays. In vitro glycosylation assays were performed as described previously17 using 200 nM 
of NleB1 or its orthologs with 1 μM of either WT GshB or GshB R256A in 50 mM Tris-HCl pH 7.4, 1 mM 
UDP-GlcNAc, 10 mM MnCl2, and 1 mM DTT. After 2 h incubation at RT, samples were subjected to western blot-
ting using an anti-R-GlcNAc monoclonal antibody (Abcam). In vivo glycosylation assays were performed using 
C. rodentium and S. enterica strains electroporated with plasmids expressing His-GshB or His-GshB(R256A). 
Transformed bacteria were grown overnight in the presence of 0.5 mM IPTG, harvested using centrifugation, 
and then His-tagged proteins were purified as described above, and then subjected to western blotting using an 
anti-R-GlcNAc monoclonal antibody (Abcam).
Bacterial growth assays. Overnight cultures were used to inoculate 50 ml of LB medium. H2O2 (2.4 mM 
for C. rodentium or 12.0 mM for S. enterica) was added to cultures when they reached an OD600 of 0.3 and bacte-
rial growth was monitored for 10–16 h at 37 °C.
GSH quantification from bacterial lysates. Bacteria were harvested by centrifugation, lysed in 50 mM 
Tris-HCl pH 7.4 supplemented with 0.5 ug/ml lysozyme, and recentrifuged. The supernatant was incubated with 
1 mM CDNB and 1 µM GST. Absorbance was recorded at 340 nm every 20 seconds for 10 minutes and OD340 data 
were converted into molar concentrations of GSH using a GST standard curve24.
In-vitro GSH assays. His-GshB or His-GshB(R256A) were purified over Ni-NTA slurries after they were 
respectively co-expressed with either NleB-FLAG or NleB(AAA)-FLAG in E. coli BL21(DE3) cells. An in vitro 
GSH assay was then prepared by first incubating GshA (1 µM) with 5 mM glycine, 5 mM cysteine, and 5 mM 
glutamate in a reaction buffer containing 50 mM Tris HCl pH 7.4, 1 mM DTT, 1 mM MgCl2, 1 mM ATP, and 3% 
DMSO. After 1 h incubation at 37 °C, the purified GshB proteins (50 nM), along with 100 nM GST and 1 mM 
CDNB were added, and glutathione formation was monitored by reading the absorbance at 340 nm as a function 
of time.
Statistical analyses. Bacterial growth assays were analyzed using non-linear regression followed by Dunn’s 
multiple comparison testing. GSH assays were analyzed using linear regression. p-values <0.05 were considered 
significant.
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